ArticleAdvanced healthcare materials2026
Micro-Nano Composite System Combining Mesenchymal Stem Cells and Pirfenidone for Endometrial Regeneration via Microenvironment Remodeling.
Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Endometrial injury remains a leading cause of female infertility, yet current clinical interventions exhibit limited regenerative efficacy. In this study, we developed a micro-nano composite system (G-H/ADSC@PDA/PFD) combining adipose-derived mesenchymal stem cell (ADSC)-laden double-network hydrogel (G-H/ADSC) microspheres with pirfenidone (PFD)-loaded polydopamine (PDA/PFD) nanoparticles to achieve synergistic stem cell and drug delivery. The microspheres were fabricated from gelatin methacryloyl (GelMA) and hyaluronic acid methacryloyl (HAMA) via droplet microfluidic technology, exhibiting favorable mechanical strength and cytocompatibility. They provide a 3D microenvironment that supports ADSC growth, proliferation, and paracrine secretion, thereby enhancing angiogenesis and modulating the inflammatory milieu. Moreover, the incorporated PDA/PFD nanoparticles enhance the adhesion of the composite system to the injured endometrial site, while efficiently scavenging reactive oxygen species. The sustained release of PFD downregulates TGF-β expression, inhibits collagen deposition and fibrotic progression, and further optimizes the regenerative niche for ADSCs. In a rat model of endometrial injury, the G-H/ADSC@PDA/PFD system significantly promoted endometrial regeneration, reduced fibrosis, restored the local microenvironment, and successfully restored fertility. This study introduces a promising combinatorial strategy for the treatment of endometrial injury and infertility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.